Natixis Bleichroeder

LOS ANGELES--(BUSINESS WIRE)-- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today reported financial results for the three months ended September 30, 2008. "We significantly broadened our drug development pipeline through our recent acquisition of Innovive Pharmaceuticals and now have six clinical-stage candidates that address large markets. These drug assets are in varying stages of clinical development and provide us with near- and longer term potential revenue generators," said Steven A. Kriegsman, CytRx President and CEO. "We are evaluating our clinical and non-clinical assets with a focus on advancing development of drug candidates to maximize shareholder value, while managing our financial profile. Among our options, we are considering programs for internal development and others that may benefit from potential strategic partnerships. We look forward to completing our evaluation later this quarter, and plan to announce our strategic plan and anticipated milestones at that time. "During the ...

NEW YORK, NY -- (MARKET WIRE) -- 10/17/08 -- Pink OTC Markets Inc., the leading electronic inter-dealer quotation system, trading technology and financial information provider for over-the-counter (OTC) securities, today announced that its OTCQX and Pink Sheets market tiers continued to show strong trading performance in the 3rd quarter 2008. Pink OTC Markets' trading and transparency services have created the largest worldwide pool of liquidity among alternative or entry level markets for the shares of public companies. In September, total dollar volume traded on the OTCQX market tier surpassed the OTC Bulletin Board (OTCBB) demonstrating strong demand for trusted companies among U.S. investors: ...

WASHINGTON--(BUSINESS WIRE)-- The Biotechnology Industry Organization (BIO) today announced that 28 renowned clinicians and investigators will be featured in Therapeutic Workshops(TM) at the Seventh Annual BIO Investor Forum on October 29-31 at the Palace Hotel in San Francisco, Calif. A distinguished panel of industry leaders hand-selected these experts to discuss biotechnology pipeline innovation and the latest in clinical strategy. The clinicians and investigators represent prestigious academic institutions and medical foundations. In addition, heads of clinical development from leading public and private biotechnology companies will participate on these panels. "This is the first year in which the BIO Investor Forum, together with Gerson Lehrman Group, has made a robust investment in inviting clinical thought leaders knowledgeable about the biotech and pharmaceutical industries to speak directly to investors," said Jim Greenwood, president and CEO of BIO. "BIO is committed to providing high-quality and independent forums where clinicians and industry leaders can drive insightful discussion on innovative clinical-stage products pioneered ...

NEW YORK--(BUSINESS WIRE)-- Wall Street Media presents an exclusive video of Mr. Benjamin W. Hulburt, President and CEO of Rex Energy Corporation, (NASDAQ: REXX), discussing their proven reserve Base which is 81% oil, enhanced Oil recovery in Lawrence Field, the largest field in Illinois, and Marcellus Shale potential in the Appalachians. ...

NEW YORK--(BUSINESS WIRE)-- Wall Street Media presents an exclusive video of Mr. Joseph J. Corasanti, CEO of CONMED Corporation, (NASDAQ: CNMD) discussing their electro surgery products, and branching out into orthopedics. Please visit the following link ...